In biotechnology, where years of research and millions of dollars can hinge on a single hypothesis, the ability to recognize when to abandon a failing approach may be as critical as the conviction to pursue it. That is the view of Philip Ashton-Rickardt, Managing Director and Chief Scientific Officer at BE Therapeutics, who has spent more than three decades navigating the uncertain terrain of academic research, biotech entrepreneurship, and corporate R&D leadership.
Ashton-Rickardt, whose career includes professorships at the University of Chicago and Imperial College London, founding Smith Therapeutics, serving as Chief Scientific Officer at Sigilon Therapeutics, and advising companies through Flagship Pioneering, contends that attachment to an idea can too easily overshadow the problem the idea was meant to solve. “You have to separate attachment to the idea from attachment to the problem,” he said. “If the problem is important, there may be several ways to approach it.”
That distinction carries significant weight in an industry where scientific programs routinely evolve as new data emerge. A hypothesis that appeared promising at the outset may need adjustment, narrowing, or outright abandonment. For Ashton-Rickardt, such pivots are not admissions of failure but evidence of learning. “Flexibility is important because changing your approach is not necessarily an admission that you failed,” he said. “Sometimes it is evidence that you learned something.”
The implications for biotech leadership are substantial. Researchers, executives, investors, and entire teams often must make decisions before all questions are answered, creating pressure on leaders to project more certainty than the evidence supports. Ashton-Rickardt advocates instead for transparency about what is known, what remains uncertain, and what would trigger a change in direction. “There is a difference between providing direction and pretending to know the future,” he said. “In biotech, there are simply too many unknowns.”
Rather than eroding confidence, that approach may strengthen it. When teams understand that new information is expected to shape decisions, they may be more willing to raise concerns, question assumptions, and share data that challenges the prevailing plan. Ashton-Rickardt’s perspective is informed by a career that has repeatedly thrust him into unfamiliar territory. Raised in a working-class family in the UK, he worked his way through university and into academic science before leaving a long-established academic post to return to Boston and start a biotech company. He has since moved between startups, established biotech firms, research organizations, and investment-backed ventures, with curiosity remaining a constant. “The people I enjoy working with tend to ask good questions, even when those questions make the project more complicated,” he said.
Today, Ashton-Rickardt’s work focuses on engineered cell therapies and treatments for neurological and other serious diseases. At BE Therapeutics and at Halyard Therapeutics, where he is co-founder and Chief Scientific Officer, he continues to translate complex scientific ideas into programs that can advance. More information about his background and work is available at Philip Ashton-Rickardt. For scientists and biotech leaders, his message is clear: conviction must remain tethered to evidence. “The goal is not to prove that your first idea was right,” he said. “The goal is to solve an important problem.” That principle, he suggests, can make scientific organizations more adaptable at a time when new tools, new data, and new therapeutic approaches are continually reshaping what is possible.
